The acute effect of palonosetron on ECG parameters in patients with cancer.

Abstract

e19686 Background: The 5-hydroxytryptamine 3 receptor antagonists are used for the prevention and treatment of chemotherpy and radiotherapy-induced emesis. Despite their effectiveness and safety profile, it was reported in many studies that they may cause electrocardiographic changes related to heart rate and repolarization. The purpose of this study is to determine acute influence of paronosetron on ECG parameters in cancer patients. Methods: Forty-seven cancer patients with normal cardiac function who received paronosetron for the prevention of chemotherapy/radiotherapy induced emesis were enrolled into this prospective study. Standard 12-lead ECG recordings were performed at baseline and 30 min after palonosetron administration. P wave durations and corrected QT intervals were measured; P wave dispersion (Pd) and QTc dispersion were calculated. Statistical comparison of quantitative data was performed by paired sample t test. A P value of <0.05 was considered to be statistically significant. Results: In comparison with baseline, no statistically significant change in any ECG parameters, including QT and RR intervals, P wave durations, Pd and QTd, was observed after infusion of Palonosetron. Conclusions: In this study palonosetron did not show any ventricular and atrial arrhythmogenic effect because of repolarization abnormalities.